Highlights from our proud history:
APP Pharmaceuticals acts decisively to increase supply and alleviate critical market shortages following two voluntary recalls from other manufacturers of propofol injection. During this time, APP has become the sole supplier and increased production of Diprivan® (propofol 1%), initiated and increased production of APP Propofol 1% (authorized generic Diprivan®). The company also supplemented supply by importing and distributing international Fresenius Propoven 1% (propofol 1%), in agreement with the FDA.
APP Pharmaceuticals acquires its first southeast manufacturing facility in Raleigh, North Carolina.
On September 10, 2008, APP Pharmaceuticals is acquired by Fresenius Kabi Pharmaceuticals Holding, Inc., making it an important part of a global leader in health care.
APP works with FDA to dramatically increase manufacturing of heparin products after another manufacturer's recall. Becomes the sole supplier of heparin sodium vials in the U.S.
APP becomes a stand-alone company known as APP Pharmaceuticals when it spins off from Abraxis BioScience.
Abraxis BioScience is established. APP Division becomes Abraxis Pharmaceutical Products (APP). Acquired Puerto Rico facility.
Abraxane™ is approved by the U.S. Food and Drug Administration and is launched.
Named Cardinal Health Manufacturer of the Year, launched 12 new products; Abraxis Oncology is formed.
Completed successful IPO, acquired U.S. marketing and exclusive manufacturing rights to Abraxane™, industry leading 12 ANDA approvals.
Acquires Fujisawa's U.S. injectable business, including manufacturing capability and products.
American Pharmaceutical Partners (APP) is established.